Slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
263.000,00 KRW | -0,57% | -3,49% | -25,39% |
Voorlopige winst- en verliesrekening: Hanmi Pharm. Co., Ltd.
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Omzet 1 | 1.114 | 1.076 | 1.206 | 1.332 | 1.491 | 1.589 | 1.738 | 1.873 |
Variatie | - | -3,39% | 12,1% | 10,42% | 11,95% | 6,56% | 9,42% | 7,77% |
EBITDA 1 | 159,3 | 110,3 | 214,5 | 254,9 | 319,1 | 347 | 372,8 | 400,4 |
Variatie | - | -30,75% | 94,44% | 18,85% | 25,19% | 8,72% | 7,45% | 7,39% |
Bedrijfsresultaat (EBIT) 1 | 103,9 | 48,68 | 127,4 | 157 | 220,7 | 251,4 | 278,7 | 307 |
Variatie | - | -53,15% | 161,68% | 23,25% | 40,56% | 13,91% | 10,85% | 10,19% |
Betaalde rente 2 | -14.325 | -28.276 | -10.854 | -15.531 | -22.239 | -20.879 | -18.193 | -16.650 |
Resultaat voor belastingen (EBT) 1 | 83,3 | 22,13 | 103,8 | 116,9 | 194 | 225,5 | 258,6 | 289,5 |
Variatie | - | -73,43% | 368,91% | 12,69% | 65,87% | 16,26% | 14,68% | 11,95% |
Nettowinst (verlies) 1 | 52,11 | 11,96 | 81,08 | 76,93 | 159,3 | 163,7 | 187,5 | 210,5 |
Variatie | - | -77,05% | 577,94% | -5,12% | 107,06% | 2,78% | 14,51% | 12,29% |
Datum van publicatie | 07-02-20 | 04-02-21 | 27-01-22 | 08-02-23 | 02-02-24 | - | - | - |
Balansprognose: Hanmi Pharm. Co., Ltd.
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoschuld 1 | 693 | 643 | 481 | 519 | 508 | 233 | 11,7 | -202 |
Variatie | - | -7,22% | -25,19% | 7,9% | -2,12% | -54,18% | -94,98% | -1.826,5% |
Datum van publicatie | 07-02-20 | 04-02-21 | 27-01-22 | 08-02-23 | 02-02-24 | - | - | - |
Verwachte kasstroom: Hanmi Pharm. Co., Ltd.
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 166,1 | 41,82 | 19,95 | 30,38 | 43,74 | 47,6 | 37,86 | 39,54 |
Variatie | - | -74,83% | -52,29% | 52,28% | 43,97% | 8,85% | -20,48% | 4,44% |
Vrije kasstroom (FCF) 1 | -153.685 | 109.719 | 181.974 | 131.890 | 172.801 | 253.481 | 226.762 | 248.386 |
Variatie | - | -171,39% | 65,85% | -27,52% | 31,02% | 46,69% | -10,54% | 9,54% |
Datum van publicatie | 07-02-20 | 04-02-21 | 27-01-22 | 08-02-23 | 02-02-24 | - | - | - |
Verwachte financiële ratio's: Hanmi Pharm. Co., Ltd.
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
EBITDA-marge (%) | 14,3% | 10,25% | 17,79% | 19,14% | 21,41% | 21,84% | 21,45% | 21,37% |
EBIT-marge (%) | 9,33% | 4,52% | 10,56% | 11,79% | 14,8% | 15,82% | 16,03% | 16,39% |
EBT-marge (%) | 7,48% | 2,06% | 8,6% | 8,78% | 13,01% | 14,19% | 14,88% | 15,45% |
Nettomarge (%) | 4,68% | 1,11% | 6,72% | 5,78% | 10,68% | 10,31% | 10,78% | 11,24% |
FCF-marge (%) | -13.800,71% | 10.198,36% | 15.088,37% | 9.903,76% | 11.590,5% | 15.955,18% | 13.044,73% | 13.258% |
Vrije kasstroom/nettoresultaat (%) | -294.925,55% | 917.443,51% | 224.446,95% | 171.451,1% | 108.485,82% | 154.825,93% | 120.958,08% | 117.990,49% |
Winstgevendheid | ||||||||
ROA | 3,54% | 0,63% | 3,51% | 4,29% | 7,65% | 9,98% | 9,67% | 9,6% |
ROE | 7,93% | 1,64% | 9,21% | 9,89% | 15,15% | 16,57% | 15,7% | 15,1% |
Financiële gezondheid | ||||||||
Hefboom (schuld/ebitda) | 4,35x | 5,83x | 2,24x | 2,04x | 1,59x | 0,67x | 0,03x | - |
Schuld/vrije kasstroom | -0x | 0,01x | 0x | 0x | 0x | 0x | 0x | - |
Kapitaalintensiteit | ||||||||
Kapitaaluitgaven/omzet (%) | 14,92% | 3,89% | 1,65% | 2,28% | 2,93% | 3% | 2,18% | 2,11% |
CAPEX / EBITDA (%) | 104,29% | 37,91% | 9,3% | 11,92% | 13,7% | 13,72% | 10,15% | 9,88% |
CAPEX / FCF (%) | -0,11% | 0,04% | 0,01% | 0,02% | 0,03% | 0,02% | 0,02% | 0,02% |
Bestanddelen per aandeel | ||||||||
Kasstroom per aandeel 1 | 996,2 | 11.901 | 15.876 | 12.773 | 17.062 | 27.118 | 23.932 | 26.768 |
Variatie | - | 1.094,63% | 33,4% | -19,54% | 33,57% | 58,94% | -11,75% | 11,85% |
Dividend per aandeel 1 | 461,9 | 471,2 | 480,6 | 490,2 | 500 | 491,6 | 491,6 | 499,3 |
Variatie | - | 2% | 2% | 2% | 2% | -1,68% | 0% | 1,56% |
Nettoactief per aandeel 1 | 57.930 | 57.329 | 63.128 | 68.632 | 76.794 | 86.570 | 101.738 | 118.473 |
Variatie | - | -1,04% | 10,11% | 8,72% | 11,89% | 12,73% | 17,52% | 16,45% |
WPA 1 | 4.170 | 939,5 | 5.270 | 7.994 | 11.522 | 12.894 | 14.638 | 16.448 |
Variatie | - | -77,47% | 460,95% | 51,69% | 44,13% | 11,91% | 13,52% | 12,37% |
Aantal aandelen (in duizend) | 12.744 | 12.732 | 12.718 | 12.703 | 12.691 | 12.680 | 12.680 | 12.680 |
Datum van publicatie | 07-02-20 | 04-02-21 | 27-01-22 | 08-02-23 | 02-02-24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
K/w-verhouding | 20,4x | 18x |
PBR-ratio | 3,04x | 2,59x |
EV/omzet | 2,25x | 1,93x |
Dividendrendement | 0,19% | 0,19% |
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers A128940
- Financiën Hanmi Pharm. Co., Ltd.